Indivior PLC

DB:2IVB Stock Report

Market Cap: €1.3b

Indivior Valuation

Is 2IVB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2IVB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2IVB (€10.2) is trading below our estimate of fair value (€233.03)

Significantly Below Fair Value: 2IVB is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2IVB?

Key metric: As 2IVB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 2IVB. This is calculated by dividing 2IVB's market cap by their current revenue.
What is 2IVB's PS Ratio?
PS Ratio1.1x
SalesUS$1.18b
Market CapUS$1.36b

Price to Sales Ratio vs Peers

How does 2IVB's PS Ratio compare to its peers?

The above table shows the PS ratio for 2IVB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.2x
DMP Dermapharm Holding
1.7x4.1%€2.0b
PSG PharmaSGP Holding
2.6x7.7%€280.6m
2FJ0 Pierrel
3.4xn/a€92.8m
0RX Redx Pharma
13.3x-37.6%€65.0m
2IVB Indivior
1.1x5.5%€1.1b

Price-To-Sales vs Peers: 2IVB is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (5.2x).

Price to Sales Ratio vs Industry

How does 2IVB's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

24 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.2.9x3.4%
2IVB Indivior
 1.1x5.5%US$1.36b
2IVB 1.1xIndustry Avg. 2.9xNo. of Companies35PS0612182430+
24 CompaniesEstimated GrowthMarket Cap
Industry Avg.2.9x21.4%
2IVB Indivior
 1.1x49.4%US$1.36b
No more companies

Price-To-Sales vs Industry: 2IVB is good value based on its Price-To-Sales Ratio (1.1x) compared to the European Pharmaceuticals industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is 2IVB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2IVB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.1x
Fair PS Ratio2.7x

Price-To-Sales vs Fair Ratio: 2IVB is good value based on its Price-To-Sales Ratio (1.1x) compared to the estimated Fair Price-To-Sales Ratio (2.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2IVB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€10.20
€16.66
+63.3%
16.5%€21.82€13.90n/a5
Nov ’25€8.20
€16.66
+103.1%
16.5%€21.82€13.90n/a5
Oct ’25€8.75
€21.14
+141.6%
11.7%€24.88€17.39n/a5
Sep ’25€11.10
€22.11
+99.2%
18.0%€29.40€17.56n/a5
Aug ’25€12.70
€23.68
+86.5%
19.3%€29.65€17.71n/a5
Jul ’25€14.90
€28.81
+93.4%
2.6%€29.78€27.77n/a4
Jun ’25€17.00
€28.48
+67.5%
2.3%€29.37€27.61n/a4
May ’25€17.00
€28.90
+70.0%
1.1%€29.12€28.47n/a3
Apr ’25€19.92
€28.92
+45.2%
1.8%€29.42€28.18n/a3
Mar ’25€20.15
€27.90
+38.5%
6.8%€29.28€25.23n/a3
Feb ’25€16.18
€28.13
+73.8%
7.9%€30.25€25.06n/a3
Jan ’25€13.68
€28.02
+104.8%
7.9%€30.13€24.96n/a3
Dec ’24€15.10
€26.32
+74.3%
11.2%€30.11€22.34n/a4
Nov ’24€18.24
€28.19
+54.6%
11.0%€31.36€23.08€8.204
Oct ’24€20.40
€28.36
+39.0%
11.0%€31.66€22.66€8.755
Sep ’24€21.40
€28.36
+32.5%
11.0%€31.66€22.66€11.105
Aug ’24€20.30
€28.96
+42.7%
3.0%€29.96€27.56€12.704
Jul ’24€20.75
€27.76
+33.8%
3.9%€29.16€26.66€14.904
Jun ’24€16.80
€28.06
+67.0%
3.8%€29.33€26.80€17.004
May ’24€17.24
€26.92
+56.1%
6.9%€28.52€23.98€17.004
Apr ’24€15.52
€26.60
+71.5%
6.6%€28.10€23.82€19.924
Mar ’24€17.37
€26.60
+53.2%
6.6%€28.10€23.82€20.154
Feb ’24€21.87
€28.44
+30.0%
4.3%€29.43€26.42€16.184
Jan ’24€20.58
€25.54
+24.1%
5.5%€27.79€24.15€13.684
Dec ’23€19.91
€25.00
+25.6%
3.3%€25.96€23.93€15.104
Nov ’23€19.36
€25.69
+32.7%
2.9%€26.83€24.74€18.244

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

7D

0.6%

1Y

4.7%

Fortrea Holdings

US$1.8b

A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.

K67

US$18.40

7D

-1.6%

1Y

-38.3%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.29

7D

-1.8%

1Y

0.2%